



an Open Access Journal by MDPI

## Insulin-Like Growth Factor-1 (IGF-1) Receptor as Drug Targets

Guest Editors:

### **Dr. Kornelia Kuźnik-Trocha**

Department of Clinical Chemistry  
and Laboratory Diagnostics,  
Faculty of Pharmaceutical  
Sciences in Sosnowiec, Medical  
University of Silesia, Katowice,  
Poland

### **Prof. Dr. Katarzyna Winsz- Szczotka**

Department of Clinical Chemistry  
and Laboratory Diagnostics,  
Faculty of Pharmaceutical  
Sciences in Sosnowiec, Medical  
University of Silesia, Sosnowiec,  
Poland

Deadline for manuscript  
submissions:

**closed (30 September 2023)**

### **Message from the Guest Editors**

Insulin-like growth factor 1 (IGF-1) plays an important role in human development, growth, and aging. IGF-1 exerts its effects through specific receptors located on cell membranes, i.e., IGF-R (insulin-like growth factor-1 and 2 receptors). Through these receptors, IGF-1 induces cell growth, affects cell survival by preventing apoptosis, and stimulates cell differentiation. Abnormal IGF signaling may lead to changes in systemic homeostasis, including cognitive dysfunction, development of neurodegenerative diseases, and most importantly, malignant transformation and tumor progression. In tumorigenesis, IGF-1 and its receptor are constitutively overexpressed. Increasing evidence suggests that the IGF axis not only promotes oncogenesis but also confers resistance to standard treatment. Given the high mortality rate of cancer patients, novel therapeutic targets are urgently needed. Hence, regulation of IGF-1/IGF-1R axis signaling appears to be a promising strategy leading to the disruption of cancer cell growth and survival.



[mdpi.com/si/128490](https://mdpi.com/si/128490)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)